Solid tumors remain largely unresponsive to immune checkpoint inhibitors, in part due to their ability to suppress the cytotoxic activity of immune cells infiltrating the tumor microenvironment. One ...
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug ...
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track ...
The concept of an antibody drug conjugate is straightforward enough: a cancer-killing drug payload attached to a targeting antibody that directs the molecule to cancer cells. Though these targeted ...
Lifordi Immunotherapeutics and other biotechnology companies are using antibodies to precisely target drugs in the body.
B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, respectively Deep and durable regressions ...
The MarketWatch News Department was not involved in the creation of this content. BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ -- Precision Biologics, Inc. announces in vitro and in vivo efficacy of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback